ESMO 2022 | Late hematological malignancies of systemic anticancer therapies

Jean Baptiste Micol, MD, PhD, Gustave Roussy, Villejuif, France, discusses the risk of developing myeloid neoplasms occurring after treatment with chemotherapy or radiation. Next-generation sequencing (NGS) may be used to detect early mutations indicative of the later development of myeloid neoplasm following therapy. Mutations in the DNA repair pathway, such as p53 or PPM1D mutations, are more at risk of developing myeloid neoplasms. Data on immune checkpoint inhibitors with targeted therapy in patients with melanoma has demonstrated an improvement in clinical outcomes. However, treatment with PARP inhibitors appears to increase the variant allelic frequency of mutations, particular in DNA damage repair genes, which could explain the increase of myeloid neoplasms in patients with PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.